A Study Of CP-690,550 In Stable Kidney Transplant Patients

Back to Search
Print
Bookmark Trial

NCT01710033

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Birmingham, Alabama, 35249-6860, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Kidney Transplant
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-70 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Medically stable kidney transplant patients 6 or more months after transplantation.

- Subjects must be on mycophenolate mofetil 1-2 gm daily

- In Cohort 3 (and 4, if conducted) in Stage 1 and the expanded cohort in Stage 2, subjects must be on a calcineurin inhibitor-free regimen.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Any rejection episodes in the preceding 3 months.


- Treated with Thymoglobulin or OKT3 for acute rejection in the past 6 months.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Kidney TransplantA Study Of CP-690,550 In Stable Kidney Transplant Patients NCT01710033
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Los Angeles, California
  5. Indianapolis, Indiana
  6. Minneapolis, Minnesota
  7. St Louis, Missouri
  8. St. Louis, Missouri
  9. Livingston, New Jersey
  10. Madison, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Kidney TransplantStudy Evaluating Cyclosporine Dose Reduction and Cyclosporine Elimination in Chinese Kidney Transplants NCT00257387
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Kidney TransplantStudy Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients NCT00137345
  1. San Diego, California
  2. San Francisco, California
  3. Denver, Colorado
  4. New Haven, Connecticut
  5. Gainesville, Florida
  6. Tampa, Florida
  7. Atlanta, Georgia
  8. Chicago, Illinois
  9. Portland, Maine
  10. Springfield, Massachusetts
  11. Detroit, Michigan
  12. New York, New York
  13. Charlotte, North Carolina
  14. Durham, North Carolina
  15. Cleveland, Ohio
  16. Cleveland, Ohio
  17. Toledo, Ohio
  18. Philadelphia, Pennsylvania
  19. Philadelphia, Pennsylvania
  20. Providence, Rhode Island
  21. Charleston, South Carolina
  22. Dallas, Texas
  23. Houston, Texas
  24. Buenos Aires, Capital Ferderal
  25. Buenos Aires, Capital Ferderal
  26. Buenos Aires, Capital Ferderal
  27. Buenos Aires, Capital Ferderal
  28. Buenos Aires, Capital Ferderal
  29. Buenos Aires,
  30. Ciudad de Bs As,
  31. Cordoba,
  32. Cordoba,
  33. Camperdown,
  34. Parkville,
  35. Randwick,
  36. Westmead,
  37. Woodville South,
  38. Woolloongabba,
  39. Wien,
  40. London, Ontario
  41. Cote du Palais, Quebec
  42. Montreal, Quebec
  43. Puente Alto,
  44. Santiago,
  45. Talca,
  46. Vina del Mar,
  47. Nicosia,
  48. Montpellier Cedex,
  49. Paris Cedex 15,
  50. Munster,
  51. Athens,
  52. Thessaloniki,
  53. Budapest,
  54. Debrecen,
  55. Pecs,
  56. Szeged,
  57. Bari,
  58. Cagliari,
  59. Torino,
  60. Oslo,
  61. Carnaxide-lisboa,
  62. Coimbra,
  63. Lisboa,
  64. Singapore,
  65. Cape Town,
  66. Cape Town,
  67. Johannesburg,
  68. Barcelona,
  69. La Coruã'a,
  70. La Laguna / Santa Cruz de Tenerife,
  71. Madrid,
  72. Madrid,
  73. Santander,
  74. Valencia,
  75. Uppsala,
  76. Taipei,
  77. Antalya,
  78. Istanbul,
  79. Izmir,
  80. Glasgow,
  81. Leicester,
  82. Manchester,
ALL GENDERS
13 Years+
years
MULTIPLE SITES
Kidney TransplantStudy Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus NCT00502242
  1. Los Angeles, California
  2. Los Angeles, California
  3. San Francisco, California
  4. Aurora, Colorado
  5. Denver, Colorado
  6. Gainesville, Florida
  7. Chicago, Illinois
  8. Iowa City, Iowa
  9. Lexington, Kentucky
  10. Portland, Maine
  11. Boston, Massachusetts
  12. Springfield, Massachusetts
  13. Springfield, Massachusetts
  14. Gosse Pointe, Michigan
  15. Buffalo, New York
  16. Valhalla, New York
  17. Cleveland, Ohio
  18. Cleveland, Ohio
  19. Harrisburg, Pennsylvania
  20. Philadelphia, Pennsylvania
  21. Philadelphia, Pennsylvania
  22. Philadelphia, Pennsylvania
  23. Providence, Rhode Island
  24. Charleston, South Carolina
  25. Capital Federal, Buenos Aires
  26. San Martin, Buenos Aires
  27. Buenos Aires,
  28. Cordoba,
  29. Córdoba,
  30. Brisbane, Queensland
  31. North Terrace,
  32. Woodville South,
  33. Linz,
  34. Rio de Janeiro, RJ
  35. Porto Alegre, RS
  36. Porto Alegre, RS
  37. Sao Paulo, SP
  38. Sao Paulo, SP
  39. Sao Paulo, SP
  40. Sao Paulo, SP
  41. Montreal, Quebec
  42. Erlangen,
  43. Szeged,
  44. Petach Tikva,
  45. Mexico City,
  46. Veracruz,
  47. Szczecin,
  48. Johannesburg, Gauteng
  49. Cape Town, Western Cape
  50. Cape Town, Western Cape
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study Of CP-690,550 In Stable Kidney Transplant Patients
Official Title  ICMJE Phase 1, Placebo-controlled, Randomized, Sequential, Parallel-group, Dose Escalation Study to Evaluate 28-day Multiple Dose Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CP-690,550 in Stable Renal Allograft Recipients
Brief Summary This was a Phase 1 dose escalation study to evaluate the safety, tolerability and pharmacokinetics of 28-day treatment of CP-690,550 in stable renal allograft recipients. In Stage 1, ascending doses of CP-690,550 were to be administered sequentially to 3-4 cohorts of subjects. After Stage 1, one dose level was to be selected for dosing in an expanded cohort in Stage 2.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Condition  ICMJE Kidney Transplant
Intervention  ICMJE
  • Drug: Placebo
    Placebo tables twice daily (BID) for 28 days
  • Drug: CP-690,550 5 mg BID
    CP-690,550 5 mg BID for 28 days
  • Drug: CP-690,550 15 mg BID
    CP-690,550 15 mg BID for 28 days
  • Drug: CP-690,550 30 mg BID
    CP-690,550 30 mg BID for 28 days
Study Arms  ICMJE
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
  • Experimental: CP-690,550 5 mg BID
    Intervention: Drug: CP-690,550 5 mg BID
  • Experimental: CP-690,550 15 mg BID
    Intervention: Drug: CP-690,550 15 mg BID
  • Experimental: CP-690,550 30 mg BID
    Intervention: Drug: CP-690,550 30 mg BID
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 16, 2012)		28
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE April 2005
Actual Primary Completion Date April 2005   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Medically stable kidney transplant patients 6 or more months after transplantation.
  • Subjects must be on mycophenolate mofetil 1-2 gm daily
  • In Cohort 3 (and 4, if conducted) in Stage 1 and the expanded cohort in Stage 2, subjects must be on a calcineurin inhibitor-free regimen.

Exclusion Criteria:

  • Any rejection episodes in the preceding 3 months.
  • Treated with Thymoglobulin or OKT3 for acute rejection in the past 6 months.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01710033
Other Study ID Numbers  ICMJE A3921007
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP